Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide oral drops for weight loss are not a licensed product in the UK. No approved formulation of semaglutide exists as a drop or liquid for weight management — the oral semaglutide that is licensed here comes as a tablet, called Wegovy. If you've seen drops sold online or on social media, they fall outside the regulated UK supply chain. What does exist, approved by the MHRA on 11 June 2026, is an oral semaglutide tablet for weight loss — the first of its kind licensed in the UK. These are prescription-only medicines, which means a prescriber must assess your suitability before any treatment can begin. This page explains what the licensed oral option actually involves, why the drops you may have read about are a concern, and how the legitimate route to treatment works.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people arrive at this question after spotting something sold as "semaglutide drops" or "oral semaglutide liquid" through Instagram adverts or online marketplaces. It is a reasonable thing to look into. The idea of a liquid that avoids injections is appealing, and the confusion is understandable given how fast this space is moving.
The honest answer is that no drop or liquid form of semaglutide has received MHRA approval for weight loss in the UK. Semaglutide is a peptide molecule that breaks down very quickly in the gut without a specific absorption technology. The tablet form approved for weight loss works because it is co-formulated with SNAC, a compound that protects the molecule and allows it to cross the stomach lining intact. If you want a fuller explanation of why the format matters, our page on semaglutide oral drops covers what these products are, why they lack MHRA approval, and what the evidence actually shows. A simple liquid or sublingual drop would not replicate this, and no clinical evidence supports such a formulation for human weight management.
Products sold as semaglutide drops have not passed the safety and efficacy standards the MHRA applies to licensed medicines. The MHRA has consistently warned the public about unlicensed weight-loss products circulating online, some of which have been found to contain entirely different substances. You can report any suspect seller through the MHRA Yellow Card scheme, which also collects reports of suspected side effects from licensed medicines.
If you have seen these products marketed, the safest step is to ignore them and look at what is actually approved, and our page on whether oral semaglutides work for weight loss is a good place to build that understanding.
The licensed product is a Wegovy tablet containing semaglutide, taken once daily. It starts at 1.5 mg and escalates through 4 mg and 9 mg to a 25 mg maintenance dose, with at least a month at each level. The titration exists for a practical reason: slowing the increase gives the gut time to adjust and reduces the nausea that is most common in the early weeks of treatment.
How you take it matters more than with most medicines. First thing in the morning, before any food or drink other than a sip of plain water (up to about 120 ml), swallow the tablet whole. Then wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. The SNAC absorption mechanism depends on a briefly empty stomach, so skipping that wait undermines the medicine's effectiveness.
One practical advantage over the injection: no refrigeration. The tablets store at room temperature, which many people find simpler to manage day to day. If the idea of switching to an oral route appeals partly because of travel or storage, that is a genuine benefit worth exploring alongside the broader picture of semaglutide tablets for weight loss, including how the dosing schedule and eligibility criteria work in practice.
The MHRA's approval covered adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure or type 2 diabetes, taken alongside a reduced-calorie diet and increased activity. Lower thresholds can apply for some ethnic backgrounds under UK guidance. A prescriber reviews all of this at consultation, BMI alone does not determine suitability.
The phase 3 evidence for oral semaglutide comes from the OASIS 4 trial, which enrolled 307 adults with obesity or overweight plus at least one weight-related condition, without diabetes, over 64 weeks. On average, participants lost around 13.6% of their body weight compared with around 2.4% in the placebo group. Among those who adhered fully throughout, the average reached approximately 16.6%. The NHS medicines page for semaglutide covers the licensed indications and patient-level safety information if you want a plain-English summary from a Tier-1 source.
Those figures are meaningful. They also come with context worth knowing. The most common side effects in the trial were gastrointestinal (nausea, diarrhoea, constipation and similar) reported in around 74% of participants on the active medicine versus around 42% on placebo. For most people these were mild to moderate and settled as the dose stabilised. The titration schedule exists partly to make this manageable rather than a reason to stop.
If you want to compare the tablet's results with those of the weekly semaglutide injection, we look at the question of semaglutide pills for weight loss in more depth separately, including how the pill format compares with injectable options and what realistic outcomes look like across different patient groups. The short version: the injectable 2.4 mg weekly dose produced around 15% average weight loss over 68 weeks in the STEP 1 trial, so the tablet is broadly comparable at maintenance, though head-to-head data are still limited.
Wegovy tablets are a prescription-only medicine. That means no pharmacy, whether physical or online, can supply them without a valid prescription from an authorised prescriber who has assessed your individual circumstances. This is not a bureaucratic inconvenience, it is what keeps the medicine safe.
At nume, the process is straightforward. You fill in a free clinical consultation, and a GPhC-registered Independent Prescriber reviews your answers the same day. Not software, not an automated system, a real clinician reads your case. If treatment is suitable and your order is in before noon on a working day, your prescription is dispatched the same day and arrives free the next working day via DPD, in plain unbranded packaging.
One transparent price covers everything: consultation, prescription, the medicine itself, delivery and 7-day-a-week aftercare. There are no subscription traps or auto-renewals. Our clinical team, overseen by our prescribers, is available if questions come up after you start. You can read more about how we work on the about us page.
If you want to understand the cost side before anything else, the Wegovy tablet pricing page sets out what the private market looks like and what a legitimate price includes. When you are ready, start your free consultation to have your case reviewed by one of our prescribers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.